GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Total Stockholders Equity

KOD (Kodiak Sciences) Total Stockholders Equity : $185.37 Mil (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences Total Stockholders Equity?

Kodiak Sciences's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $185.37 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kodiak Sciences's Book Value per Share for the quarter that ended in Sep. 2024 was $3.52. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kodiak Sciences's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.40.

Kodiak Sciences Total Stockholders Equity Historical Data

The historical data trend for Kodiak Sciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences Total Stockholders Equity Chart

Kodiak Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial 345.36 860.75 663.32 436.17 265.78

Kodiak Sciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 302.42 265.78 241.19 214.51 185.37

Kodiak Sciences  (NAS:KOD) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kodiak Sciences's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(185.37-0)/52.6231
=3.52

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kodiak Sciences's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(10.196 + 63.239) / 185.37
=0.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kodiak Sciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Total Stockholders Equity
Comparable Companies
CCCC CTMX ACXP VTGN ANVS ORMP CLDI CSBR STTK OMER OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
KOD:Mexico K27:Germany
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Website
https://www.kodiak.com
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
John A. Borgeson officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Jason Ehrlich officer: See Remarks 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth director, 10 percent owner, officer: Chairman, President and CEO 1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker director, 10 percent owner BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director, 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang officer: See Remarks 2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang director 2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek director P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016